In this interview, a principal scientist from a top 10 pharma company discusses the use of digital pathology in biopharma, touching upon the current practices, challenges, and vendor satisfaction. The interviewee's organization primarily uses digital pathology to scan tissue sections stained with H&E and immunohistochemistry, encompassing both human and animal model samples. They have shifted focus towards internal solutions for digital pathology rather than relying on service providers. The distribution of digital pathology usage within the organization is expected to shift more towards clinical applications in the coming years. They currently use digital pathology across various therapeutic areas, including GI, rheumatology, fibrosis, and dermatology. The interviewee predicts that the use of immunofluorescence will increase due to the introduction of new multiplex fluorescent modalities. Challenges faced in the digital pathology space include standardization across different scanners, data storage, and retrieval costs. The interviewee identifies is highly familiar with 3DHISTECH, Proscia, 4D Path, PathAI, Visiopharm, and Indica labs, and provides satisfaction ratings for various vendors. Overall, the interview provides valuable insights into the current state and future prospects of digital pathology in biopharma.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.